^○Takumi NAKAJIMA¹, Kequan FU^{1, 2}, Yoshiaki MIYAMOTO¹, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 2. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China)

^○Ryo FUKUMORI, Kensaku OTA, Tsuneyuki YAMAMOTO, Taku YAMAGUCHI (Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Nagasaki International University)

^○Yuki HONSHUKU, Ryoki SAITO, Takuji SOGA, Natsuko HITORA-IMAMURA, Masabumi MINAMI (Lab. of Pharmacology, Department of Pharmacy, Hokkaido university, Hokkaido, Japan)

^○June TOGAMI¹, Kumi SUZUKI¹, Makiko MIYAMOTO¹, Daisuke NISHIZAWA², Kazutaka IKEDA², Atsuko KAWAI³, Eiji YOSHIHARA¹, Kazuhiko IWAHASHI^{1, 2, 4} (1. Lab. of Physiology, Department of Medical Technology, Graduate School of Environmental Health, Azabu University, Kanagawa, Japan, 2. Addictive Substance Project, Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, 3. Koutokukai Total Health Clinic, Yamagata, Japan, 4. Health Administration center, Azabu University, Kanagawa, Japan)

^○Makiko MIYAMOTO¹, Kumi SUZUKI¹, June TOGAMI¹, Eiji YOSHIHARA¹, Daisuke NISHIZAWA², Atsuko KAWAI³, Kazutaka IKEDA², Kazuhiko IWAHASHI^{1, 2, 4} (1. Laboratory of Physiology (Project of Neurophysiology), Course of Environmental Health Science, Graduate School of Environmental Health, Azabu University, Kanagawa, Japan, 2. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, 3. Koutokukai Total Health Clinic, Yamagata, Japan, 4. Health Administration Center, Azabu University, Kanagawa, Japan)